Phase 1b Multicenter Study of Carfilzomib With Lenalidomide and Dexamethasone in Relapsed Multiple Myeloma

PHASE1CompletedINTERVENTIONAL
Enrollment

84

Participants

Timeline

Start Date

May 31, 2008

Primary Completion Date

May 31, 2013

Study Completion Date

January 31, 2016

Conditions
Relapsed Multiple Myeloma
Interventions
DRUG

Carfilzomib

Carfilzomib for Injection was administered intravenously over 10 minutes on Days 1, 2, 8, 9, 15, and 16 of a 28-day cycle for the first 12 cycles. Each dose of Carfilzomib for Injection was normalized to body surface area.

DRUG

Lenalidomide

Lenalidomide was administered orally on Days 1 to 21 of each 28-day cycle.

DRUG

Dexamethasone

Dexamethasone 40 mg orally or intravenous equivalent was administered 30 minutes to 4 hours before carfilzomib on Days 1, 8, and 15, as well as on Day 22 of each 28-day cycle.

Trial Locations (12)

10021

Cornell University, New York

33612

H. Lee Moffitt Cancer Center & Research Institute, Tampa

44718

Gabrail Cancer Center, Canton

53226

Medical College of Wisconsin, Milwaukee

60611

Northwestern University, Chicago

77030

MD Anderson Cancer Center, Houston

90048

Cedars Sinai Medical Center, Los Angeles

90813

Pacific Shores Medical Group, Long Beach

94143

University of California San Francisco, San Francisco

07601

Hackensack University Medical Center, Hackensack

98103-1204

Fred Hutch Cancer Research Center, Seattle

H3T 1E2

Jewish General Hospital, Montreal

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Amgen

INDUSTRY

NCT00603447 - Phase 1b Multicenter Study of Carfilzomib With Lenalidomide and Dexamethasone in Relapsed Multiple Myeloma | Biotech Hunter | Biotech Hunter